Examining the Role of GLP-1 Receptor Agonists in Alzheimer's Research

This chapter explores the impact of GLP-1 receptor agonist loraglutide on cognitive decline in early-stage Alzheimer's patients. The discussion centers on a phase 2b clinical trial that showed promising results in slowing cognitive decline, despite missing a key metabolic endpoint.